Results for the substance lazertinib

Lazertinib is an anticancer medicine used for locally advanced or metastatic non-small cell lung cancer with specific EGFR mutations, such as exon 19 deletion or the exon 21 L858R mutation. It is commonly given together with amivantamab as part of a targeted treatment plan.

The medicine is an EGFR inhibitor and blocks signals that help tumour cells grow. For patients, genetic testing of the cancer is essential before treatment starts. The choice of therapy also depends on overall health, previous treatments and the expected risk of side effects.

Lazertinib is taken by mouth once daily, exactly as prescribed. Because use with amivantamab can increase the risk of blood clots, your doctor may recommend preventive measures and close monitoring. Do not start new medicines, including supplements, without telling your oncology team.

Side effects may include rash, itching, dry skin, nail problems, diarrhoea, mouth inflammation, tiredness, swelling, muscle pain and abnormal liver tests. Seek urgent medical help for chest pain, shortness of breath, a new or worsening cough, swelling in one leg, or sudden neurological symptoms.